Nanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and Asthma

Wadhwa, Ridhima; Aggarwal, Taru; Thapliyal, Noopur; Chellappan, Dinesh Kumar; Gupta, Gaurav; Gulati, Monica; Collet, Trudi; Oliver, Brian G.; Williams, Kylie; Hansbro, Philip M.; Dua, Kamal; Maurya, Pawan Kumar

doi:10.1016/b978-0-12-818823-1.00005-3

Cited by 17 publications

(12 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic manifestations within the known types of lung cancer are mediated by increased levels of inflammatory proteins within them. The key molecular and cellular factors that play a major role in the inflammation‐to‐cancer axis are the pro‐inflammatory factors, namely, tumor necrosis factor alpha (TNF‐α), interleukin (IL)‐1β, and IL‐6 (Gomes et al., 2014; Wadhwa et al., 2019). There exists a large body of research data which reveals the likely association of cytokine deregulation with the development and evolution of malignant processes and mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

et al. 2020

Self Cite

View full text Add to dashboard Cite

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. Practical applications Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of

show abstract

Section: Introductionmentioning

confidence: 99%

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Reviews related to the importance and use of nanoparticles for respiratory diseases are available [ 15 ]; However, a comprehensive summary of novel drug delivery systems has not been presented as yet. Domej et al reviewed the general relevance of free radicals in the development and progression of both COPD and pulmonary emphysema as well as novel perspectives on therapeutic options.…”

Section: Introductionmentioning

confidence: 99%

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Song

2020

J Nanobiotechnol

View full text Add to dashboard Cite

Oxidative stress is significantly involved in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Combining antioxidant drugs or nutrients results in a noteworthy therapeutic value in animal models of COPD. However, the benefits have not been reproduced in clinical applications, this may be attributed to the limited absorption, concentration, and half-life of exogenous antioxidants. Therefore, novel drug delivery systems to combat oxidative stress in COPD are needed. This review presents a brief insight into the current knowledge on the role of oxidative stress and highlights the recent trends in novel drug delivery carriers that could aid in combating oxidative stress in COPD. The introduction of nanotechnology has enabled researchers to overcome several problems and improve the pharmacokinetics and bioavailability of drugs. Large porous microparticles, and porous nanoparticle-encapsulated microparticles are the most promising carriers for achieving effective pulmonary deposition of inhaled medication and obtaining controlled drug release. However, translating drug delivery systems for administration in pulmonary clinical settings is still in its initial phases.

show abstract

“…38 T-cell factor (TCF), the transcription factor of the WNT signaling pathway, was known for its invaluable part in the growth of T-cells and thymus proliferation. [39][40][41][42] TCF-1, which is encoded by the TCF-7 gene, TCF-3, 4, and LEF-1, are the four members of the TCF family. 43,44 59 Furthermore, it has been shown in a review that Fzd6 controls both canonical and non-canonical pathways, interacts with heterotrimeric proteins Gαi1/Gαq and that after stimulation with Wnt5a, the complex is dissociated.…”

Section: Wnt/beta-catenin Pathway In Psoriatic Skinmentioning

confidence: 99%

Beta‐catenin non‐canonical pathway: A potential target for inflammatory and hyperproliferative state via expression of transglutaminase 2 in psoriatic skin keratinocyte

Gupta

Singh²,

Tiwari

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic, local as well as a systemic, inflammatory skin condition. Psoriasis influences the quality of life up to 3.8% of the population and occurs often between 15 and 30 years of age. Specific causes are linked to psoriasis, including the interleukin IL-23/IL-17 Axis, human antigen leucocyte (HLA), and tumor necrosis factor-α (TNF-α). Secukinumab is a monoclonal antibody that specifically binds and neutralizes IL-17A required in the treatment of Psoriasis. The signaling pathways of Wnt govern multiple functions of cell-like fate specification, proliferation, polarity, migration, differentiation with their signaling controlled rigorously, given that dysregulation caused by various stimuli, can lead to alterations in cell proliferation, apoptosis, and human inflammatory disease. Current data has supported non-canonical Wnt signaling pathways in psoriasis development, particularly Wnt5a activated signaling cascades. These interconnected factors are significant in interactions between immune cells, keratinocytes, and inflammatory factors due to a higher degree of transglutaminase 2, mediated by activation of the keratinocyte hyperproliferation of the psoriatic patient's epidermis. This study discusses the pathology of Wnt5a signaling and its involvement in the epidermal inflammatory effects of psoriasis with other related pathways.

show abstract

Nanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and Asthma

Cited by 17 publications

References 108 publications

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Beta‐catenin non‐canonical pathway: A potential target for inflammatory and hyperproliferative state via expression of transglutaminase 2 in psoriatic skin keratinocyte

Contact Info

Product

Resources

About